Study Title
A Phase 2 Study of Veliparib (ABT-888, IND# 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
Protocol ID
ACNS1721
Disease (Sub Disease)
Anaplastic Astrocytoma
Glioblastoma
Malignant Glioma
Glioblastoma
Malignant Glioma
Diagnosis Stage
New diagnosis
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 2
Age Eligibility
3 Years to 25 Years
International registry ID's
NCT03581292
| Study Title | A Phase 2 Study of Veliparib (ABT-888 IND# 139199) and Local Irradiation Followed by Maintenance Veliparib and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations |
|---|---|
| Protocol ID | ACNS1721 |
| Disease (Sub Disease) | Anaplastic Astrocytoma Glioblastoma Malignant Glioma |
| Diagnosis Stage | New diagnosis |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT03581292 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 31/10/2018 |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 3 Years to 25 Years |
| International registry ID's | NCT03581292 |